Novo Nordisk (NVO) is making strategic moves to expand its reach in Japan by offering obesity treatments such as Wegovy to patients who are willing to pay out-of-pocket. This initiative is part of the company's efforts to enhance access to GLP-1 drugs, despite facing challenges such as a significant drop in market value. The company's assets under management have fallen to DKK 694 billion (€93 billion) from DKK 1,060 billion (€142 billion) in 2024. Additionally, Novo Nordisk is contending with increased competition from Eli Lilly (LLY) and cheaper alternatives, resulting in a decline of about 48% in its stock value in 2025 and another ~26% in 2026.
No comments:
Post a Comment
Note: Only a member of this blog may post a comment.